AMBS Financials 07/16/2014 06:29:43 Amarantus Bio

AMBS Financials 07/16/2014 06:29:43
Amarantus Bioscience Holdings, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue - - 224 192
Cost of Revenue - - - -
Gross Profit - - 224 192
Operating Expenses
Research and Development 2,089 584 1,178 490
Sales, General and Admin. 3,622 3,506 2,786 924
Non-Recurring Items - - - -
Other - - - -
Operating Income (5,711) (4,090) (3,740) (1,223)
Income From Continuing Operations
Add'l Income/Expense Items (6,790) 473 315 94
Earnings Before Interest and Tax (12,501) (3,617) (3,425) (1,128)
Interest Expense 2,631 1,518 1,015 79
Earnings Before Tax (15,132) (5,136) (4,440) (1,208)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (15,132) (5,136) (4,440) (1,208)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (15,132) (5,136) (4,440) (1,208)
Preferred Stock and Other Adjustments (38) - - -
Net Income Applicable to Common Shareholders (15,170) (5,136) (4,440) (1,208)